Tempest Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
TPST$0.37+3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-In · Deficit · TotalStockholders' | |||||
|---|---|---|---|---|---|
| Shares(1) | Amount(1) | Capital(1) | Accumulated | Equity (Deficit) | |
| BALANCE — December 31, 2023 | 1,695,788 | $2 | $192,029 | $(165,263) | $26,768 |
| Issuance of common stock for cash (net of issuance cost of $1,105) | 1,663,554 | 1 | 28,590 | — | 28,591 |
| Share-based compensation | — | — | 5,303 | — | 5,303 |
| Issuance of common stock under equity plan awards | 23,090 | — | 307 | — | 307 |
| Net loss | — | — | — | (41,843) | (41,843) |
| BALANCE — December 31, 2024 | 3,382,432 | $3 | $226,229 | $(207,106) | $19,126 |
| Issuance of common stock for cash (net of issuance cost of $535) | 1,204,774 | 2 | 6,045 | — | 6,047 |
| Share-based compensation | — | — | 3,118 | — | 3,118 |
| Issuance of pre-funded warrants (net of issuance cost of $416) | 334,000 | — | 3,309 | — | 3,309 |
| Issuance of common stock warrants (net of issuance cost of $165) | — | — | 1,283 | — | 1,283 |
| Issuance of common stock under equity plan awards | 5,955 | — | 47 | — | 47 |
| Net loss | — | — | — | (26,262) | (26,262) |
| BALANCE — December 31, 2025 | 4,927,161 | $5 | $240,031 | $(233,368) | $6,668 |
(1) Results, including shares of common stock, have been adjusted to reflect theone-for-thirteen stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.